(Date:12/4/2008)...h anniversary of drive to eliminate lymphatic fila...zole tablet and grant to The Carter Center , ,...rstCall/ -- In a meeting today with former U.S. Pr...rter, as well as global health thought leaders fro...SK ) announced that it has made a $250,000 donatio...
(Date:12/4/2008)...ewswire/ -- Two researchers who translate math int...n stopping breast cancer in its,tracks are this y...tific,Distinction in basic research and clinical ...onio, Susan G. Komen for the Cure(R) announced tod...in/prnh/20070122/NYM084LOGO ) , Award recip...
(Date:12/4/2008)...c. 4 MiddleBrook,Pharma... that it has opened its,administrative and sales ...wn,facility will continue to house certain person...ch and development group. The newly leased 14,971...se up to 60 employees as MiddleBrook,grows. , ...
(Date:12/4/2008)...., Dec. 4 Universal Heal...oday that they have expanded their,Board of Trust... Vice,President of Universal Health Services, Inc...ears of experience in healthcare leadership roles.... Co-head of the Acute Care Division,since 2007 an...
Breaking Medicine News(10 mins):Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4(Date:12/3/2008).... Jude treatment alleviates long-term anemia and o...plications , , MEMPHIS, Tenn., Dec. 3 /PRN...nsert a corrective gene into mouse blood cells, sc...have alleviated sickle cell disease pathology. In ...ted mice showed essentially no difference from nor...
(Date:12/3/2008)..., Del., Dec. 3 Isogen, a contract ...erile filling, announced it has retained a,strate... to meet the global,biopharma demand for Isogen,s...d a successful first round series of capital,inve...acility in Q1 2009 to,deliver on the previously u...
(Date:12/3/2008)...EGO, Dec. 3 Vical Incorp...sive, binding letter of intent with EIP,Eczacibas...g of the company,s,Allovectin-7(R) immunotherapeu...epublic of Northern Cyprus. EIP has agreed to obta...ritory and to pay Vical upfront and milestone paym...
(Date:12/2/2008)...DGE, Mass., Dec. 2 Biopu...that the U.S. Naval Medical Research Center,(NMRC...n (FDA) a revised,investigational new drug (IND) ...mpany,s oxygen therapeutic Hemopure(R) [hemoglobin...ttlefield treatment of trauma patients. The study ...
Breaking Medicine Technology:Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Sage Software Healthcare Inc Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 7649 1Sage Software Healthcare Inc Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 7649 2Infant Development Program from EASY Baby Takes On the Sixty Percent Increase in Developmental Delays in Children 7647 1Infant Development Program from EASY Baby Takes On the Sixty Percent Increase in Developmental Delays in Children 7647 2Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 1Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 2Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 3Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 1Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 2Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 3... 66.1 weeks for the,satraplatin arm compared with ...0.64 (95% CI: 0.51-0.79, p<0.001), representing,a ...sion, MARTINSRIED/MUNICH, Germany, May 21, 2007 /P...ER, Colo. -- GPC Biotech AG and,Pharmion Corporati...data from the double-blind, randomized satraplatin...
...ut of ten patients taking,once-daily Lialda remain...N, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A,...ion study (303),presented at the British Society o...and in March 2007 showed Shire plc,s,Lialda(mesala...ients. Today, secondary endpoints of study 303 wer...
Other Medicine Technology:Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8Merocel Ophthalmic Products provide the surgeon with fiber free products for fluid,control and safe cleaning of fine microsurgical instruments. The exclusive Merocel,material is highly absorbent,
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Accu-Temp Cauteries provide a broad selection of tip styles for cauterization in a wide variety of ophthalmic procedures. Each single use cautery is packaged sterile, complete with a safety cap to lo
Medicine Products: